In the title compound, C(16)H(12)N(2)O(8)·2C(3)H(7)NO, the complete tricyclic compound is generated by a crystallographic centre of symmetry. In the crystal, the tricycle is linked to two adjacent N,N-dimethyl-formamide solvent mol-ecules by O-H⋯O hydrogen bonds.

The title compound, C(35)H(38)N(4)O(3), was prepared as a spiro-lactam ring formation of rhodamine dye for comparison with a ring-opened form. The xanthene ring system is approximately planar. The dihedral angles formed by the spiro-lactam and phenol rings with the xanthene ring system are 85.7 and 109.4°, respectively. Each of the mol-ecules in the crystal structure contains one intra-molecula...

The asymmetric unit of the title compound, C(17)H(15)NO(4), contains two independent mol-ecules with similar geometric parameters. In both mol-ecules, the conformation of the cyclo-hexene ring is half-chair, while the pyrrolidinone ring adopts an envelope conformation with the γ-carbon atom of the α-pyrrolidinone ring as the flap. In the crystal, O-H⋯O hydrogen bonds between the carb-oxylic and...

In the title compound, C(16)H(18)ClNO(3)S, the six-membered ring has a boat conformation. The two five-membered rings with the bridging O atom adopt envelope conformations, whereas the N-containing five-membered ring adopts a twisted conformation. In the crystal, C-H⋯O hydrogen bonds link the mol-ecules into a three-dimensional network.

We report a novel synthetic compound JTP-27536 [(+)-1,3-dihydroxy-2-hydroxymethylpropyl-2-ammonium 2-[(R)-3-cyclohexyl-1-phenylpropyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylate monohydrate] as an inhibitor of immunoglobulins (Igs) and interleukin (IL)-5 production in vitro and in vivo. JTP-27536 inhibited IgE production in mouse and human B cells with IC50 values of 2.5 and 2.1 microM, r...